USF TrialNet Clinical Center

描述(申请人提供)：1型糖尿病试验网络的目标是通过一个高度协作的网络来延缓或防止T1D高危人群的T1D发展，并保护T1D患者的细胞功能，该网络旨在识别T1D的高危人群，确定他们是否有资格参加预防试验和进行“新发病”的干预试验。USF糖尿病中心一直是佛罗里达大学卓有成效的分支机构，并与南佛罗里达大学的TrialNet协调中心合作，开发新的方法来增加TrialNet的注册人数。该中心由一个致力于多学科的团队组成，通过最先进的、专注的临床和临床研究进行操作 为1400多名儿童和成人T1D患者提供服务的设施。此外，它还建立了糖尿病护理提供者的区域协作网络，可以接触到数以千计的现有和新发的T1D患者。PI的经验，包括担任印第安纳大学DPT-1区域招聘中心主任、印第安纳大学TrialNet临床中心前主任和预防路径研究主席，以及他与T1D利益相关者的成功接触，使他能够为TrialNet做出重要贡献，并使他对TrialNet目前的限制和扩展机会有了宝贵的洞察。资助USF TrialNet临床中心将大大加强他作为指导委员会投票成员、临床领导委员会潜在成员和临床网络中心合作者的身份参与TrialNet。资金还将允许在佛罗里达州中西部地区显着扩大TrialNet的招募，并使未开发的高危人口能够获得这一机会。美国联邦糖尿病中心致力于开展临床研究，寻求改善T1D的发展，这从我们TrialNet筛查活动的显著增加、我们的糖尿病临床试验数量以及我们与TrialNet TNCC合作开发创新筛查计划中可见一斑。我们作为TrialNet临床中心的参与将使我们能够显著扩大我们目前代表TrialNet进行的合作努力。

DESCRIPTION (provided by applicant): The objectives of Type 1 Diabetes TrialNet are to delay or prevent the development of T1D in persons at risk and to preserve ¿-cell function in those with T1D possessing residual ¿-cell function through a highly collaborative network designed to identify individuals at-risk for T1D and to determine their eligibility for- and enrollment into prevention trials and to perform "new- onset" intervention trials. The USF Diabetes Center has been a very productive Affiliate of the University of Florida and has engaged with the TrialNet Coordinating Center at the University of South Florida to develop novel approaches to increase TrialNet enrollment. The Center is comprised of a committed multi-disciplinary team operating from a state-of-the-art, dedicated clinical and clinical research facility serving greater than 1,400 pediatric and adult patients with T1D. In addition, it has established a regional collaborative network of diabetes care providers with access to thousands of additional existing- and new-onset T1D patients. The PI's experience, including roles as the Indiana University DPT-1 Regional Recruitment Center Director, former Director of the Indiana University TrialNet Clinical Center, and as Chair of the Pathway to Prevention Study, and his successful engagement of T1D stakeholders, have enabled him to make vital contributions to TrialNet and has provided him with valuable insight into TrialNet's current limitations and opportunities for expansion. Funding of the USF TrialNet Clinical Center will greatly enhance his involvement in TrialNet as a voting member of the Steering Committee, potential member of the Clinical Leadership Committee, and collaborator of the Clinical Network Hub. Funding will also permit marked expansion of TrialNet recruitment in the West Central Florida region and gain access to hereto for untapped at-risk populations. The USF Diabetes Center's commitment to pursue clinical studies seeking to ameliorate the development of T1D is evidenced by the marked increase in our TrialNet screening activity, the number of our diabetes clinical trails, and our work with the TrialNet TNCC to develop innovative screening initiatives. Our participation as a TrialNet Clinical Center will permit us to markedly expand our current collaborative efforts on behalf of TrialNet.